Abstract
Sickle cell disease (SCD) is a genetic disorder that affects millions of individuals worldwide. Chronic anemia, hemolysis and vasculopathy are the most common symptoms that arise from hemoglobin (Hb) polymerization, which is the primary event of SCD. The above process can lead to erythrocyte sickling. Therapeutic options for SCD remain limited, and novel therapies are still being evaluated for their effectiveness in particular populations. Sphingosine-1-phosphate (S1P), a significant bioactive sphingolipid, acts as a potent signal mediator, modulating several cellular functions. The potential role of erythrocyte-S1P in enhancing SCD severity has been previously reported by multiple studies. Therefore, the present review article aimed to summarize the effects of S1P on the progression of SCD and provide strategies to modulate this process. More specifically, it focused on erythrocyte-S1P as a potential target for reducing the complications associated with SCD, thus paving the way for the development of novel therapeutic strategies for SCD.